Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Alousi AM, et al. Among authors: shpall ej. Biol Blood Marrow Transplant. 2015 May;21(5):906-12. doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7. Biol Blood Marrow Transplant. 2015. PMID: 25667989 Free PMC article. Clinical Trial.
Transplantation of ex vivo expanded cord blood.
Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK. Shpall EJ, et al. Biol Blood Marrow Transplant. 2002;8(7):368-76. doi: 10.1053/bbmt.2002.v8.pm12171483. Biol Blood Marrow Transplant. 2002. PMID: 12171483 Clinical Trial.
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. de Lima M, et al. Among authors: shpall ej. Blood. 2004 Aug 1;104(3):857-64. doi: 10.1182/blood-2004-02-0414. Epub 2004 Apr 8. Blood. 2004. PMID: 15073038 Free article.
Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support.
Nieto Y, Franklin WA, Jones RB, Berman SI, Pellom J, Barón AE, Shpall EJ. Nieto Y, et al. Among authors: shpall ej. Biol Blood Marrow Transplant. 2004 Jun;10(6):415-25. doi: 10.1016/j.bbmt.2004.02.004. Biol Blood Marrow Transplant. 2004. PMID: 15148495 Free article.
Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant.
Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-Vasquez V, McSweeney PA, Bearman SI, Murphy J, Jones RB. Nieto Y, et al. Among authors: shpall ej. Clin Cancer Res. 2004 Aug 1;10(15):5076-86. doi: 10.1158/1078-0432.CCR-04-0117. Clin Cancer Res. 2004. PMID: 15297410
529 results